0A57 Stock Overview
An in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
T2 Biosystems, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.57 |
| 52 Week High | US$7.43 |
| 52 Week Low | US$0.42 |
| Beta | 0.38 |
| 11 Month Change | -40.25% |
| 3 Month Change | -81.46% |
| 1 Year Change | -84.07% |
| 33 Year Change | -99.98% |
| 5 Year Change | n/a |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A57 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 18.6% | 0.8% | 0.4% |
| 1Y | -84.1% | -13.1% | 7.9% |
Return vs Industry: 0A57 underperformed the UK Biotechs industry which returned -14.2% over the past year.
Return vs Market: 0A57 underperformed the UK Market which returned 9% over the past year.
Price Volatility
| 0A57 volatility | |
|---|---|
| 0A57 Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A57's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0A57's weekly volatility has decreased from 18% to 13% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 113 | John Sperzel | www.t2biosystems.com |
T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens.
T2 Biosystems, Inc. Fundamentals Summary
| 0A57 fundamental statistics | |
|---|---|
| Market cap | US$12.04m |
| Earnings (TTM) | -US$42.95m |
| Revenue (TTM) | US$7.68m |
1.6x
P/S Ratio-0.3x
P/E RatioIs 0A57 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A57 income statement (TTM) | |
|---|---|
| Revenue | US$7.68m |
| Cost of Revenue | US$26.70m |
| Gross Profit | -US$19.03m |
| Other Expenses | US$23.93m |
| Earnings | -US$42.95m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.04 |
| Gross Margin | -247.83% |
| Net Profit Margin | -559.52% |
| Debt/Equity Ratio | -101.8% |
How did 0A57 perform over the long term?
See historical performance and comparison